Clinical Trial Update: Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of sotrovimab as pre-exposure prophylaxis for COVID-19 in hematopoietic stem cell transplant recipients; the trial was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Solid Tumor

Drugs mentioned

• Sotrovimab (sotrovimab)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Status: TERMINATED | Results posted: 2025-02-13